Drug intelligence / Profile preview

BR1017-2

Development stage: Unknown
Lead developer: Boryung

Overview

BR1017-2 is a drug that has been investigated in a completed clinical study (NCT05372380) to evaluate its drug-drug interactions with BR1017-1 in healthy volunteers. The study mentions conditions such as hypertension and hypercholesterinemia, suggesting these as potential therapeutic areas for the drug. However, the specific mechanism of action, developer, or detailed indications for BR1017-2 are not provided in the available context.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on BR1017-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1017-2.

Explore the full profile